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Many types of tumors are organized in a hierarchy of heterogeneous cell populations, with only a small proportion of cancer
stem cells (CSCs) capable of sustaining tumor formation and growth, giving rise to diﬀerentiated cells, which form the bulk of
the tumor. Proof of the existence of CSC comes from clinical experience with germ-cell cancers, where the elimination of a subset
of undiﬀerentiated cells can cure patients (Horwich et al., 2006), and from the study of leukemic cells (Bonnet and Dick, 1997;
Lapidot et al., 1994; and Yilmaz et al., 2006). The discovery of CSC in leukemias as well as in many solid malignancies, including
breast carcinoma (Al-Hajj et al. 2003; Fang et al., 2005; Hemmati et al., 2003; Kim et al., 2005; Lawson et al., 2007; Li et al., 2007;
Ricci-Vitiani et al., 2007; Singh et al., 2003; and Xin et al., 2005), has suggested a unifying CSC theory of cancer development.
The reported general insensitivity of CSC to chemotherapy and radiation treatment (Bao et al., 2006) has suggested that current
anticancer drugs, which inhibit bulk replicating cancer cells, may not eﬀectively inhibit CSC. The clinical relevance of targeting
CSC-associated genes is supported by several recent studies, including CD44 targeting for treatment of acute myeloid leukemia
(Jin et al., 2006), CD24 targeting for treatment of colon and pancreatic cancer (Sagiv et al., 2008), and CD133 targeting for
hepatocellular and gastric cancer (Smith et al., 2008). One promising approach is to target CSC survival signaling pathways, where
leukemia stem cell research has already made some progress (Mikkola et al., 2010).
1. Cancer Stem Cells
In the past few years, a growing body of experimental
evidence has been reported in favor of the hypothesis that
many types of tumors are organized in a hierarchy of het-
erogeneous cell populations, with only a small proportion
of cancer stem cells (CSCs) capable of sustaining tumor
formation and growth, giving rise to diﬀerentiated cells,
which form the bulk of the tumor. Proof of the existence of
CSC comes from clinical experience with germ-cell cancers,
where the elimination of a subset of undiﬀerentiated cells
can cure patients [1], and from the study of leukemic cells
[2–4]. The discovery of CSC in leukemias as well as in many
solid malignancies, including breast carcinoma [5–13], has
suggested a unifying CSC theory of cancer development.
The reported general insensitivity of CSC to chemotherapy
and radiation treatment [14] has suggested that current
anticancer drugs, which are developed extensively based on
their activity to inhibit bulk replicating cancer cells, may not
eﬀectivelyinhibitCSC,andthattargetingCSCwillbehelpful
in eradicating tumors more eﬃciently. The clinical relevance
of targeting CSC-associated genes is supported by several
recent studies, including CD44 targeting for treatment of
acute myeloid leukemia [15], CD24 targeting for treatment
of colon and pancreatic cancer [16], and CD133 targeting
f o rh e p a t o c e l l u l a ra n dg a s t r i cc a n c e r[ 17]. One promising
approach is to target CSC survival signaling pathways, where
leukemia stem cell research has already made some progress
[18].
2. Breast Cancer Stem Cells
Breast cancer, a complex and heterogeneous disease, is the
leading cause of cancer death in women. More than a million
new cases are diagnosed every year worldwide [19]. Despite
combined treatment with surgery, radiotherapy, and anti-
cancer drugs, many breast cancer patients will ultimately2 Journal of Oncology
develop metastatic disease, at present incurable. While many
studies have attempted to demonstrate the presence of breast
CSC(BCSC) basedoncellsurfacemarkerproﬁles,consensus
on their phenotypic characterization is still missing. In light
of recent experimental evidence, the idea of a universal
markerorcombinationofmarkersabletoidentifyandisolate
BCSC from all breast cancers seems unrealistic. This is not
surprising, because breast cancer is not a single disease; it
is comprised of various histological subtypes, with variable
clinical presentations and diﬀerent underlying molecular
signatures. On the basis of global gene expression proﬁling,
breastcancerhasbeendividedintoﬁvemajormolecularsub-
types: luminal A, luminal B, HER2+, basal-like, and normal
breastlike [20–22]. Each subtype is associated with a peculiar
natural history and treatment responsiveness. Thus, the
prognosis of patients with basal-like tumors is worse than
for patient with luminal A tumors [22, 23]. In addition
to intertumor heterogeneity, there is also a high degree
of intratumor diversity. Speciﬁcally, a single tumor at any
given time can contain tumor cell populations with distinct
molecular proﬁles and biological properties. Intratumor
diversity has been reported as early as at the stage of ductal
carcinomainsitu[24,25].HeterogeneityofCSCpopulations
has been demonstrated in other types of tumors, such as
glioblastoma, where diﬀerent CSC subpopulations have been
described [26, 27]. Park et al. [23], based on their recent
immunohistochemical analyses of 12 markers in almost 400
ductal breast cancers, concluded that the frequency of breast
cancercellspositiveforstemcell-likeandmorediﬀerentiated
markers varies according to tumor subtype and histologic
stage. A concise review of the literature for the most studied
BCSC markers follows.
3.OriginalCD44+/CD24−/low BCSC Phenotype
A CD44+/CD24−/low subpopulation of CSC was originally
identiﬁed from Al-Haji et al. [5], using cells from metastatic
pleuraleﬀusionsofbreastcarcinomapatients.Theirpresence
has subsequently been conﬁrmed in additional studies,
especially in the MCF7 cell line [28]. Following removal of
nonepithelial cells, cells with the CD44+CD24−/low pheno-
type were highly enriched in their ability to initiate tumors
compared with unsorted cells. Further enrichment was
possible by additionally sorting the cells for expression of
the ESA (epithelial cell adhesion molecule) antigen. CD44+/
CD24−/low were also able to serially propagate the tumors
in mice, demonstrating capacity for self-renewal. CD24 is a
heavily glycosylated, mucin-type protein linked to the cell
membrane via glycosyl-phosphatidylinositol [29]. Since it
can bind P-selectin, a lectin expressed by vascular endothe-
lium and platelets, it has been suggested to play an important
role in the metastatic process [30, 31]. CD44 is a trans-
membrane glycoprotein, present in several isoforms, that
normally takes part in cell-cell and cell-matrix adhesion
interactions, and cell migration. CD44 binds hyaluronic acid
as well as collagen, ﬁbronectin, laminin, and chondroitin
sulfate, important components of the extracellular matrix,
as well as the cytokine osteopontin [32]. Many cancer cell
types as well as their metastases express high levels of
CD44 and/or CD44 variants. Since the blockage of CD44-
ligandinteractioninhibitslocaltumorgrowthandmetastatic
spread, CD44 may confer a growth advantage to breast can-
cer cells. The initial reports that only the CD44+CD24−/low
subpopulation of human breast cancer cells contains BCSC
have been challenged by subsequent studies [33, 34]. Honeth
etal.[34]d et ect edaCD44 +CD24−/low subpopulationinonly
31% of 240 human breast cancer samples analyzed, with
astrongassociationwiththebasal-likephenotype.Creighton
et al. [35] reported that a gene expression signature common
to both CD44+/CD24−/low and mammosphere-forming cells
was mainly present in breast cancer of the recently identi-
ﬁed claudin-low molecular subtype, which is characterized
by expression of many epithelial-mesenchymal transition-
(EMT-) associated genes. In addition, contrasting results
have been reported by diﬀerent groups in regard to the inva-
siveness of CD44+CD24+ compared with CD44+CD24−/low
cells [30, 36–38]. We [39] and other groups [33, 34]h a v e
found that CD24 is not a consistent breast cancer stem
cell marker. In particular, in a human breast carcinoma
model originated from bone marrow micrometastases of
a breast cancer patient [40], we have recently shown that the
s.c growth of CD24+ and CD24− sorted breast cancer cell
subpopulationsandtheirsingle-cellclonesresultedinsimilar
take and growth rates [39]. Single cell-sorted CD24− and
CD24high MA-11 gave rise in vitro to cell populations with
heterogeneous CD24 expression. Also, all tumor xenografts
derived from CD24+ and CD24− cells expressed CD24 on
their cell surface in vivo [39]. The rapid up- and downreg-
ulation of putative stem cell markers is not novel; Monzani
et al. [41] have recently shown that after injecting CD133+
melanoma cells in NOD-SCID mice, most of the tumors
became CD133 negative. Furthermore, growing these cells
in vitro after few passages, they re-expressed CD133. That
CD24 is rapidly and transiently downregulated under certain
culture conditions reconciles the apparent discrepancy of the
promalignant and proinvasiveness role of CD24 with the
CD24−/low phenotypeofbreastCSC[5,28,30,33,34,37,38].
Interestingly, CD24 silencing did not change tumorigenicity,
suggesting that the level of expression of CD24 is associated
with but does not contribute to tumorigenicity [39]. These
ﬁndings, together with the widespread expression of CD44,
strongly suggest that the CD44+CD24−/low phenotype is not
suﬃcient to characterize BCSC.
4. Mammosphere Formation
Based on the mammosphere-forming assay in serum-free
medium on nonadherent plastic used for culture of normal
mammary epithelial cells, Ponti and colleagues employed
a similar approach to derive mammospheres from human
breast cancers [28]( T a b l e1). They found in the malignant
mammospheresthesameCD44+CD24− phenotypereported
by Al-Hajj et al. [5], and the capacity to diﬀerentiate to both
luminal and basal/myoepithelial lineages. Fournier et al. [42,
52] showed the importance of 3D cultures for the generation
of breast cancer signatures. Rappa et al. [39, 53]f o u n da nJournal of Oncology 3
Table 1
Breast cancer stem cell markers References
CD44+CD24−/low Al-Haji et al. [5]; Ponti et al. [28]; Honeth et al. [34]
Mammosphere-forming ability Ponti et al. [28]; Fournier and Martin [42]; Rappa and Lorico [39]
Hoechst 33342 side population Hirschmann-Jax et al. [43]; Patrawala et al. [44]
Aldehyde dehydrogenase Ginestier et al. [45]; Charafe-Jauﬀr e te ta l .[ 46]
CD133 Xiao et al. [47]; Wright et al. [48]; Storci et al. [49]
Integrins Vassilopolous et al. [50]; Vaillant et al. [51]
increased expression of surface markers associated with the
stem cell phenotype and of oncogenes in cell lines and clones
cultured as spheroids versus adherent cultures; also, sphe-
roid-forming cells displayed increased tumorigenicity and
an altered pattern of chemosensitivity. MAPK, Notch, and
Wnt-associatedgenes,alongwiththeBCSCmarker,aldehyde
dehydrogenase,werefoundoverexpressedinmammospheres
from breast cancer cell lines.
5. Side Population
The ability to exclude the Hoescht 33342 ﬂuorescent dye
from the intracellular compartment, originally developed
by the Goodell lab to isolate a “side population” (SP) of
hematopoietic cells highly enriched in haematopoietic stem
cells[54],resultsfromtheexpressionofATP-bindingcassette
(ABC) transporters. A similar SP, enriched in cells with the
ability to initiate tumors in immune deﬁcient mice, has
been identiﬁed in breast cancer cell lines [43, 44]. Also,
enrichmentfortheprogenitorcell-containingSPafterirradi-
ation was observed in breast cancer cell lines [55]. However,
unresolved issues with potential toxicity of Hoechst 33342 to
non-SP cells hinder the further application of this functional
assay to the identiﬁcation of BCSC subpopulations.
6. Aldehyde Dehydrogenase
Another candidate marker for a breast CSC phenotype is
aldehyde dehydrogenase (ALDH). ALDHs are a family of
enzymes involved in the detoxiﬁcation of a wide variety
of aldehydes to their corresponding weak carboxylic acids,
including xenobiotic aldehydes, such as cyclophosphamide
[56]. Since there are 19 ALDH genes in humans, organized
into 11 groups, with functional overlap, a functional enzy-
matic assay, rather than immunohistochemistry methods, is
generally used to identify ALDH+ cells, employing the com-
mercial reagent ALDEFLUOR (STEMCELL Technologies
Inc, Vancouver, BC, Canada). The ALDEFLUOR substrate,
BODIPYaminoacetaldehyde(BAAA),isconvertedbyALDH
in the cells into a ﬂuorescent molecule, that accumulates
in cells in the presence of eﬄux inhibitors, allowing
cells with high ALDH activity to be easily identiﬁed.
Ginestier et al. [45] reported that only 20% to 25% of
breast carcinomas express ALDH. Of these, on average,
5% of the cells are positive for ALDH. A minor overlap
(1%) between the ALDEFLUOR-positive population and
the CD44+/CD24−/low subpopulation was observed in that
study. However, as few as 20 cells expressing both BCSC
phenotypes were required to generate a tumor in immun-
odeﬁcient mice. In the same study, ALDH− cells were not
tumorigenic up to 50,000 cells, and ALDH+ tumors were
associated with high histological grade, ERBB2 overexpres-
sion, absence of estrogen and progesterone receptor expres-
sion, and poor clinical outcome, based on overall survival.
These observations led the authors to propose that ALDH
expression in a subset of tumors may reﬂect transformation
of ALDH+ stem or early progenitor cells in these tumors.
By contrast, ALDH− tumors may be generated by the trans-
formation of ALDH− progenitor cells. In apparent contrast
with the relatively low percentage of ALDH+ breast cancers
in vivo, Charafe-Jauﬀret et al. [46]r e p o r t e dt h a t2 3o f3 3c e l l
lines derived from normal and malignant mammary tissue
contained an ALDEFLUOR+ population that displayed stem
cell properties in vitro and in NOD/SCID xenografts. Also,
another study from the same group demonstrated that
ALDH1 expression can be an independent prognostic factor
for predicting metastases in inﬂammatory breast cancer and
thatCSCshavetheabilitytoreconstitutetheheterogeneityof
the primary tumor at the metastatic site [57].
7. Prominin-1(CD133)
Recent data from several laboratories suggest that CD133-
positivity identiﬁes a subgroup of breast CSC [47–49].
CD133, named Prominin-1 for its prominent location on
the protrusion of cell membranes, is the ﬁrst identiﬁed gene
in a class of novel pentaspan transmembrane glycoproteins
[58, 59]. It deﬁnes a broad population of somatic stem
and progenitor cells, including those derived from the
hematopoietic and nervous system [60]. In addition, it has
been found to be elevated in peripheral blood of patients
with metastatic cancer [61]. CD133 is much more restricted
in expression compared with other CSC markers such as
CD44 and ALDH, which are more universally expressed in
normal as well as cancer cells. A subpopulation of CD133+
CSC has been identiﬁed in colon carcinoma [11]a n d
glioblastoma [12]. Although CD133 is considered the most
important CSC marker identiﬁed so far, very little is known
about its physiological function(s), except in the eye, where,
together with protocadherin 21, a photoreceptor-speciﬁc
cadherin, and with actin ﬁlaments, it forms a complex
involved in photoreceptor disk morphogenesis [62]. Also,
current knowledge about the regulatory mechanisms and the4 Journal of Oncology
interaction of CD133 with other cellular proteins and
biochemicalpathwaysisveryscarce.Wehavereported[63]in
malignant melanoma that shRNA-mediated downregulation
h a dp r o f o u n de ﬀects on human CD133-expressing cancer
cells; in vitro CD133 knockdown slowed cell growth, reduced
cell motility, and decreased the formation of spheroids under
stem cell-like growth conditions; in vivo the downregula-
tion of CD133 severely reduced the capacity of the cells
to metastasize, particularly to the spinal cord [63]. Successful
immunotoxin targeting of CD133 in hepatocellular and gas-
tric cancer xenografts has also been reported [17]. These
data suggest that CD133, in addition to its role as a CSC
marker,isanimportantcancertherapeutictarget.Expression
of CD133 has recently been reported in 22 out of 25 cases of
inﬂammatory breast cancer (IBC), a particularly lethal form
of breast cancer characterized by exaggerated lymphovas-
cular invasion [47]. CD133 expression was also detected in
BCSC-enriched spheroids of the MARY-X xenograft model
of IBC [47]. Interestingly, MARY-X spheroids expressed
a BCSC proﬁle characterized as CD44+/CD24−/low,A L D H +,
and CD133+ [47]. Also, in BRCA1-associated breast cancer
cell lines, CD133+ sorted cells harbor CSC properties such
as a greater colony-forming eﬃciency, higher proliferative
output, and greater ability to form tumors in NOD/SCID
mice [48]. In addition, basal-like breast carcinoma cells
from patients and stem/progenitor cells of mammospheres
isolated from ductal breast carcinoma express high levels of
CD133 [49].
8.Integrins
Mouse mammary stem cells have recently been identiﬁed
by employing the integrins CD29 (β1) and CD49f (α6) in
combination with CD24 [64, 65]. Based on the hypothesis
thatmarkersusedfornormalmammarystemcellscouldalso
work for the isolation of mammary CSC, Vassilopolous et al.
[50] used CD24/CD29 or CD24/CD49f to identify a subpop-
ulation of mammary tumor cells. In addition, a mammary
progenitor cell population has been shown to express high
levels of integrin CD61 (β3), which is only marginally
expressed in normal mammary epithelia [66]. Employing
three diﬀerent mouse models of mammary tumorigenesis,
Vaillant et al. [51] found that in two of them (MMTV-wnt-
1, and p53+/−), CD61 identiﬁed a subpopulation that was
highly enriched for tumorigenic capability relative to the
CD61− subset.
9. Conclusions
It is conceivable that breast cancer heterogeneity derives,
at least in part, from the existence of distinct BCSC
populations. Available markers should be further tested in
combination; additional markers,or speciﬁcgene signatures,
are deﬁnitely needed to deﬁne, and possibly target, BCSC
populationsofthediﬀerentbreastcancersubtypes.However,
the possibility of (i) marker downregulation/silencing; (ii)
generation of marker-negative from marker-positive BCSC
cells; (iii) coexistence of diﬀerent BCSC subpopulations in
the same tumor or at diﬀerent metastatic sites should be
considered before designing novel anti-BCSC strategies.
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